<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603209</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY2019000317</org_study_id>
    <nct_id>NCT04603209</nct_id>
  </id_info>
  <brief_title>Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer</brief_title>
  <official_title>Research Registry for Intra-Operative Radiotherapy (IORT) During Breast Conserving Surgery in Patients With in Situ and Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Wayne Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, registry study that will enroll all women with early stage breast&#xD;
      cancer who will be treated with intraoperative radiotherapy (IORT) during breast-conserving&#xD;
      surgery. The purpose of this study is to further validate the long-term effectiveness and&#xD;
      safety of this treatment method. We aim to assess short and long-term patient outcomes&#xD;
      associated with IORT, including perioperative complications, local and distance disease&#xD;
      recurrences, as well as disease-free survival and overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">October 3, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Disease Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Presence of recurrent tumor in ipsilateral breast or distant site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>10 years</time_frame>
    <description>survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years</time_frame>
    <description>survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Breast Carcinoma in Situ</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>IORT</arm_group_label>
    <description>Participants will undergo partial mastectomy for treatment of early stage breast cancer. IORT will then be delivered following surgical resection of the tumor. After surgery, participants are followed under routine care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative Radiation Therapy (IORT)</intervention_name>
    <description>IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery</description>
    <arm_group_label>IORT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any individual aged ≥ 18 years with early stage breast cancer who is determined to be&#xD;
        suitable candidates for breast-conserving surgery and IORT by a multidisciplinary team.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical stage Tis, T1, or T2(≤ 3cm), N0, M0 (AJCC Classification)&#xD;
&#xD;
          -  Unifocal Disease&#xD;
&#xD;
          -  Candidate for breast-conserving surgery&#xD;
&#xD;
          -  Recommended treatment by multidisciplinary team&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical stage T3-4, N1-3, M1&#xD;
&#xD;
          -  Multifocal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janie Grumley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Wayne Cancer Institute, Providence Saint John's Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janie Grumley, MD</last_name>
    <phone>(310) 582-7100</phone>
    <email>janie.grumley@providence.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Wayne Cancer Institute, Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janie Grumley, MD</last_name>
      <phone>310-582-7100</phone>
      <email>janie.grumley@providence.org</email>
    </contact>
    <investigator>
      <last_name>Robert Wollman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Chaiken, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John Wayne Cancer Institute</investigator_affiliation>
    <investigator_full_name>Janie Grumley</investigator_full_name>
    <investigator_title>Director of the Comprehensive Breast Program, Margie Petersen Breast Center</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Early-stage Breast Cancer</keyword>
  <keyword>Intraoperative Radiotherapy</keyword>
  <keyword>IORT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

